在人类内皮细胞中,胰岛素受体-胰岛素类似生长因子-1受体异构体的小分子调节
Chloe G Myers1, Hema Viswambharan1, Natalie J Haywood1
1Leeds Institute for Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, United Kingdom.
Molecular and cellular endocrinology
|October 17, 2024
概括
研究人员开发了一种新型的小分子,可以有效地降低胰岛素受体:胰岛素样生长因子-1受体 (IR:IGF-1R) 在内皮细胞中的混合形成. 这一发现增强了胰岛素信号通路,并为2型糖尿病等疾病提供了潜在的治疗途径.
科学领域:
- 内分泌学和分子生物学
- 心血管研究研究心血管研究
- 药理学 药理学是指药理学的学科.
背景情况:
- 胰岛素受体 (IR) 和胰岛素样生长因子-1受体 (IGF-1R) 在内皮细胞中形成混合受体,这一过程的功能含义尚不清楚.
- 混合受体形成可能在内皮功能障碍中发挥作用,特别是在2型糖尿病等代谢疾病的背景下.
研究的目的:
- 研究内皮细胞中IR:IGF-1R混合受体的功能.
- 开发和描述一种能够减少内皮细胞中IR:IGF-1R混合形成的小分子.
主要方法:
- 高通量小分子选,利用阿波混合结构的同质模型.
- 用已识别的小分子处理的内皮细胞的西部抹杀和定量PCR (qPCR) 分析.
- 对下游信号通路的评估,包括Akt酸化和PI3-激酶活性.
主要成果:
- 发现了一种新型含素的小分子,可以在人静脉内皮细胞 (HUVEC) 中将IR:IGF-1R杂交物减少50%以上,而不会影响总IR或IGF-1R水平.
- 这种小分子降低了酸丁3-酶 (PI3K) 的p85α调控子单元的表达,并增加了基底和刺激的Akt血清酸化.
- 在2型糖尿病患者的软静脉内皮细胞 (SVEC) 中观察到混合体受体表达升高,小分子在患者衍生细胞中显著减少了这些混合体.
结论:
- 一个一流的小分子有效地抑制了人体内皮细胞中IR:IGF-1R混合受体的形成.
- 抑制混合受体增强胰岛素诱导的Akt酸化,可能通过减弱PI3K信号传递的抑制作用.
- 这些发现表明,针对与内皮功能障碍相关的疾病,如2型糖尿病,针对IR:IGF-1R杂交的治疗策略.
更多相关视频
相关概念视频
Insulin: The Receptor and Signaling Pathways
1.2K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.2K
Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
Glucagon-like Receptor Agonists
301
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
301
Hormones Regulating Blood Glucose
3.1K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.1K
Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K


